Cure8 research brief
This Taiwanese multicenter real-world study reports high 52-week clinical response and remission rates, sustained one-year drug persistence, and meaningful fistula healing with ustekinumab in patients with Crohn’s disease and ulcerative colitis—data relevant to patients and clinicians evaluating biologic options in Asian practice.
Adult patients with Crohn’s disease or ulcerative colitis, clinicians prescribing biologics, researchers interested in real-world biologic outcomes and IBD in Asian populations.
This analysis used data from a national IBD registry and included 379 patients treated with ustekinumab (301 with Crohn’s, 78 with UC). Clinical response and remission rates at week 52 were high among patients with available follow-up; fistula closure was observed in a subset with active fistulizing disease.
One-year drug persistence exceeded 80% in both cohorts, and no new safety signals were reported in the abstract. The study is retrospective and registry-based, which can reflect routine practice but has limitations compared with randomized trials (for example, potential selection bias and missing data).
The abstract summarizes outcomes through week 52 but does not provide full protocol details in this brief summary.
Structured content depth: abstract. The findings are from a retrospective registry study and reflect observational real-world data; full methods and detailed safety/adverse event data are in the full paper.
Review the original publication for the complete reporting, methods, and context.
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
This EC approval means ustekinumab (Stelara) is now an authorised treatment option in the EU for certain children and adolescents with moderate–severe Crohn’s disease who have not responded to other treatments.
This study provides real-world data on how well ustekinumab is kept on treatment and its safety in an Arab IBD population—information that can help patients and clinicians understand longer-term use outside clinical...
The study addresses a practical question for people with IBD: whether sequencing anti-TNF therapy after a biologic from a different class affects how well the anti-TNF works. Shorter durability — especially in ulcerative...
